0001181431-12-047606.txt : 20120827 0001181431-12-047606.hdr.sgml : 20120827 20120827213007 ACCESSION NUMBER: 0001181431-12-047606 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120823 FILED AS OF DATE: 20120827 DATE AS OF CHANGE: 20120827 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: JACOBSEN MICHAEL A CENTRAL INDEX KEY: 0001529087 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 121058239 MAIL ADDRESS: STREET 1: 3450 MONTE VILLA PARKWAY CITY: BOTHELL STATE: WA ZIP: 98021 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: OR FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3450 MONTE VILLA PARKWAY STREET 2: SUITE 101 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 425-354-5038 MAIL ADDRESS: STREET 1: 3450 MONTE VILLA PARKWAY STREET 2: SUITE 101 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 4 1 rrd354465.xml X0306 4 2012-08-23 0 0000873303 Sarepta Therapeutics, Inc. SRPT 0001529087 JACOBSEN MICHAEL A 3450 MONTE VILLA PARKWAY, SUITE 101 BOTHELL WA 98021 0 1 0 0 VP of Finance and PAO Common Stock 2012-08-23 4 A 0 7500 0 A 7500 D Stock Option (Right to Buy) 10.08 2012-08-23 4 A 0 48500 0 A 2022-08-23 Common Stock 48500 48500 D Restricted stock units (RSUs). 25% of the RSUs will vest on the one (1) year anniversary of August 23, 2012 (the "Vesting Commencement Date"), and 1/48th of the RSUs will vest in equal monthly installments thereafter, such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date. The RSUs are subject to acceleration provisions in the event of certain termination scenarios as more specifically set forth in an agreement between the Issuer and the Reporting Person. 25% of the shares subject to the option will vest and become exercisable on the one (1) year anniversary of August 23, 2012 (the "Vesting Commencement Date"), and 1/48th of the total number of shares will vest and become exercisable in equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. /s/ Michael A. Jacobsen 2012-08-27